Insulin glargine/lixisenatide

From WikiMD's WELLNESSPEDIA

(Redirected from Soliqua)

Insulin glargine/lixisenatide is a combination medication used in the treatment of Type 2 diabetes. It is a combination of insulin glargine, a long-acting insulin, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Composition[edit]

The medication is composed of two active ingredients: insulin glargine and lixisenatide. Insulin glargine is a long-acting insulin analog that helps to control blood sugar levels in individuals with diabetes. Lixisenatide is a GLP-1 receptor agonist that slows gastric emptying and increases insulin secretion.

Uses[edit]

Insulin glargine/lixisenatide is used to improve blood sugar control in adults with Type 2 diabetes. It is used when diet and exercise alone does not provide adequate blood sugar control.

Side Effects[edit]

Common side effects of insulin glargine/lixisenatide include hypoglycemia, allergic reactions, injection site reactions, and gastrointestinal problems. Severe side effects may include pancreatitis and heart failure.

Precautions[edit]

Before starting treatment with insulin glargine/lixisenatide, patients should inform their healthcare provider about all their medical conditions and medications. It is not recommended for use in patients with Type 1 diabetes or for the treatment of diabetic ketoacidosis.

Interactions[edit]

Insulin glargine/lixisenatide may interact with other medications, which can affect how it works or increase the risk of serious side effects. Patients should inform their healthcare provider about all the medications they are currently taking.

Dosage[edit]

The dosage of insulin glargine/lixisenatide is individualized based on the patient's blood sugar control, response to therapy, and other medical conditions.

Storage[edit]

Insulin glargine/lixisenatide should be stored in the refrigerator, away from light and heat. It should not be frozen.

See Also[edit]


Stub icon

This WikiMD article can only be edited by registered and verified editors. You can log in or register.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Insulin_glargine/lixisenatide&oldid=6533607"